Korro Bio (KRRO) Competitors

$9.97 -0.21 (-2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$9.95 -0.02 (-0.20%)

As of 05:42 PM Eastern

KRRO vs. CADL, CLYM, TLRY, EIKN, and ARVN

Should you buy Korro Bio stock or one of its competitors? MarketBeat compares Korro Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Korro Bio include Candel Therapeutics (CADL), Climb Bio (CLYM), Tilray Brands (TLRY), EIKN (EIKN), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.

How does Korro Bio compare to Candel Therapeutics?

Korro Bio (NASDAQ:KRRO) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Korro Bio presently has a consensus price target of $27.43, indicating a potential upside of 175.11%. Candel Therapeutics has a consensus price target of $18.00, indicating a potential upside of 127.85%. Given Korro Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Korro Bio is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.73
Candel Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Candel Therapeutics had 11 more articles in the media than Korro Bio. MarketBeat recorded 12 mentions for Candel Therapeutics and 1 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.93 beat Candel Therapeutics' score of 0.06 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Candel Therapeutics has lower revenue, but higher earnings than Korro Bio. Candel Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	22.50	-$117.26M	-$11.67	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Korro Bio has a beta of 3.07, meaning that its share price is 207% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.59, meaning that its share price is 159% less volatile than the broader market.

Candel Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Candel Therapeutics' return on equity of -60.42% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Candel Therapeutics	N/A	-60.42%	-41.33%

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Candel Therapeutics beats Korro Bio on 9 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Climb Bio has higher earnings, but lower revenue than Korro Bio. Climb Bio is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Korro Bio	$6.39M	22.50	-$117.26M	-$11.67	N/A

Climb Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Climb Bio's return on equity of -31.45% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Climb Bio has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.07, indicating that its stock price is 207% more volatile than the broader market.

In the previous week, Climb Bio had 16 more articles in the media than Korro Bio. MarketBeat recorded 17 mentions for Climb Bio and 1 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.93 beat Climb Bio's score of 0.69 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Climb Bio currently has a consensus target price of $20.30, suggesting a potential upside of 105.47%. Korro Bio has a consensus target price of $27.43, suggesting a potential upside of 175.11%. Given Korro Bio's higher possible upside, analysts clearly believe Korro Bio is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Korro Bio	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.73

Summary

Climb Bio beats Korro Bio on 10 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Tilray Brands?

Korro Bio (NASDAQ:KRRO) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Tilray Brands had 6 more articles in the media than Korro Bio. MarketBeat recorded 7 mentions for Tilray Brands and 1 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.93 beat Tilray Brands' score of 0.45 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Korro Bio has higher earnings, but lower revenue than Tilray Brands. Korro Bio is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	22.50	-$117.26M	-$11.67	N/A
Tilray Brands	$821.31M	0.74	-$2.19B	-$13.65	N/A

Korro Bio presently has a consensus price target of $27.43, suggesting a potential upside of 175.11%. Tilray Brands has a consensus price target of $11.50, suggesting a potential upside of 122.01%. Given Korro Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Korro Bio is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.73
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Tilray Brands has a net margin of -156.51% compared to Korro Bio's net margin of -1,834.48%. Tilray Brands' return on equity of -3.31% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Tilray Brands	-156.51%	-3.31%	-2.42%

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 9.4% of Tilray Brands shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 0.8% of Tilray Brands shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Korro Bio has a beta of 3.07, indicating that its stock price is 207% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Summary

Korro Bio beats Tilray Brands on 11 of the 17 factors compared between the two stocks.

How does Korro Bio compare to EIKN?

Korro Bio (NASDAQ:KRRO) and EIKN (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

13.2% of Korro Bio shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Korro Bio currently has a consensus target price of $27.43, suggesting a potential upside of 175.11%. EIKN has a consensus target price of $25.20, suggesting a potential upside of 114.47%. Given Korro Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Korro Bio is more favorable than EIKN.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.73
EIKN	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

EIKN has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. EIKN's return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
EIKN	N/A	N/A	N/A

EIKN has lower revenue, but higher earnings than Korro Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	22.50	-$117.26M	-$11.67	N/A
EIKN	N/A	N/A	N/A	N/A	N/A

In the previous week, EIKN had 1 more articles in the media than Korro Bio. MarketBeat recorded 2 mentions for EIKN and 1 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.93 beat EIKN's score of -0.46 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
EIKN	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Korro Bio beats EIKN on 7 of the 11 factors compared between the two stocks.

How does Korro Bio compare to Arvinas?

Arvinas (NASDAQ:ARVN) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

95.2% of Arvinas shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 7.3% of Arvinas shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Arvinas had 32 more articles in the media than Korro Bio. MarketBeat recorded 33 mentions for Arvinas and 1 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.93 beat Arvinas' score of 0.24 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	10 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Korro Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas currently has a consensus price target of $14.69, suggesting a potential upside of 67.34%. Korro Bio has a consensus price target of $27.43, suggesting a potential upside of 175.11%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	3 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Korro Bio	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.73

Arvinas has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Korro Bio has a beta of 3.07, meaning that its share price is 207% more volatile than the broader market.

Arvinas has higher revenue and earnings than Korro Bio. Arvinas is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.16	-$80.80M	-$3.32	N/A
Korro Bio	$6.39M	22.50	-$117.26M	-$11.67	N/A

Arvinas has a net margin of -247.54% compared to Korro Bio's net margin of -1,834.48%. Arvinas' return on equity of -44.38% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Summary

Arvinas beats Korro Bio on 10 of the 17 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRRO vs. The Competition

Export

Metric	Korro Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$143.77M	$2.97B	$6.24B	$12.22B
Dividend Yield	N/A	1.98%	2.80%	5.30%
P/E Ratio	-0.85	17.22	20.66	25.25
Price / Sales	22.50	245.11	546.68	70.71
Price / Cash	N/A	56.35	27.48	37.27
Price / Book	1.83	3.93	9.67	6.63
Net Income	-$117.26M	$74.99M	$3.56B	$335.32M
7 Day Performance	-13.00%	-5.07%	-1.91%	-1.83%
1 Month Performance	-30.72%	-7.93%	-2.65%	-1.16%
1 Year Performance	-34.02%	31.85%	31.17%	28.31%

Korro Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRRO Korro Bio	2.9834 of 5 stars	$9.97 -2.1%	$27.43 +175.1%	-32.6%	$143.77M	$6.39M	N/A	70	Analyst Forecast
CADL Candel Therapeutics	3.8596 of 5 stars	$8.67 -2.1%	$18.00 +107.7%	+63.9%	$635.62M	N/A	N/A	60	Earnings Report Analyst Upgrade Analyst Revision
CLYM Climb Bio	3.2543 of 5 stars	$11.11 -0.1%	$20.30 +82.8%	+737.2%	$633.41M	N/A	N/A	9
TLRY Tilray Brands	3.1232 of 5 stars	$5.42 -1.7%	$11.50 +112.4%	+7.5%	$631.12M	$821.31M	N/A	2,842
EIKN EIKN	N/A	$11.13 +11.8%	$25.20 +126.5%	N/A	$611.55M	N/A	N/A	384	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Korro Bio (KRRO) Competitors

KRRO vs. CADL, CLYM, TLRY, EIKN, and ARVN

How does Korro Bio compare to Candel Therapeutics?

Summary

How does Korro Bio compare to Climb Bio?

Summary

How does Korro Bio compare to Tilray Brands?

Summary

How does Korro Bio compare to EIKN?

Summary

How does Korro Bio compare to Arvinas?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Korro Bio (KRRO) Competitors

KRRO vs. CADL, CLYM, TLRY, EIKN, and ARVN

How does Korro Bio compare to Candel Therapeutics?

Do analysts prefer KRRO or CADL?

Does the media refer more to KRRO or CADL?

Which has better valuation & earnings, KRRO or CADL?

Which has more risk and volatility, KRRO or CADL?

Is KRRO or CADL more profitable?

Do insiders & institutionals believe in KRRO or CADL?

Summary

How does Korro Bio compare to Climb Bio?

Do insiders and institutionals have more ownership in CLYM or KRRO?

Which has higher valuation and earnings, CLYM or KRRO?

Is CLYM or KRRO more profitable?

Which has more risk and volatility, CLYM or KRRO?

Does the media refer more to CLYM or KRRO?

Do analysts recommend CLYM or KRRO?

Summary

How does Korro Bio compare to Tilray Brands?

Does the media prefer KRRO or TLRY?

Which has stronger earnings and valuation, KRRO or TLRY?

Do analysts prefer KRRO or TLRY?

Is KRRO or TLRY more profitable?

Do insiders & institutionals have more ownership in KRRO or TLRY?

Which has more volatility & risk, KRRO or TLRY?

Summary

How does Korro Bio compare to EIKN?

Do insiders and institutionals have more ownership in KRRO or EIKN?

Do analysts recommend KRRO or EIKN?

Is KRRO or EIKN more profitable?

Which has stronger valuation & earnings, KRRO or EIKN?

Does the media prefer KRRO or EIKN?

Summary

How does Korro Bio compare to Arvinas?

Do institutionals & insiders hold more shares of ARVN or KRRO?

Does the media favor ARVN or KRRO?

Do analysts recommend ARVN or KRRO?

Which has more risk and volatility, ARVN or KRRO?

Which has preferable valuation and earnings, ARVN or KRRO?

Is ARVN or KRRO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools